Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY® study

Abstract Background Guidelines from 2016 onwards recommend early use of SGLT2i or GLP-1 RA for patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), to reduce CV events and mortality. Many eligible patients are not treated accordingly, although data are lacking for Central and Easter...

Full description

Bibliographic Details
Main Authors: Martin Prázný, Lyudmila Suplotova, Janusz Gumprecht, Zdravko Kamenov, Tibor Fülöp, Alexey Medvedchikov, Doron Rosenzweig, Milos Aleksandric
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Cardiovascular Diabetology
Subjects:
Cardiovascular disease (CVD)
Cardiovascular outcomes trials (CVOTs)
Cardiovascular safety
Chronic kidney disease (CKD)
Dipeptidyl peptidase-4 inhibitors (DPP4i)
Glucagon-like peptide-1 receptor agonists (GLP-1 RA)
Online Access:https://doi.org/10.1186/s12933-022-01631-4

Internet

https://doi.org/10.1186/s12933-022-01631-4

Similar Items